Kerensa Thorne

Risk Factors for Renal Dysfunction in Type 2 Diabetes

Ravi Retnakaran, C A Cull, Kerensa Thorne et al. · Diabetes · 2006 · 934 citations · Full text

Medicine, Nephrology, Diabetology +14

Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes

Rury R. Holman, Kerensa Thorne, Melanie J. Davies et al. · New England Journal of Medicine · 2007 · 709 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Saye Khoo, Richard J. Fitzgerald, Sean Ewings et al. · Journal of Antimicrobial Chemotherapy · 2021 · 118 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double‐blind, placebo‐controlled trial

Clare Whicher, Hermione Price, Peter Phiri et al. · Diabetes Obesity and Metabolism · 2021 · 70 citations

Pharmacy, Pharmacotherapy, Psychiatry +17

Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial

Clare Whicher, Hermione Price, Peter Phiri et al. · Trials · 2019 · 27 citations · Full text

Medicine, Pharmacology, Psychiatry +17